產品描述: | BQ-123 is a selective endothelin A receptor (ETA) antagonist with IC50 of 7.3 nM. Phase 2. |
靶點: |
Endothelin Receptor;EndothelinReceptor |
體內研究: |
In rats, BQ-123 (1 mg/kg, i.v.) ameliorates myocardial ischemic-reperfusion injury. In rats with pentylenetetrazole (PTZ)-induced tonic-clonic seizures, BQ-123 (3 mg/kg, i.v.) potently impedes the formation and spread of seizure. In pregnant C57BL/6 mice, BQ-123 (6.7 mg/kg, i.p.) prevents LPS-induced preterm birth in mice via the induction of uterine and placental IL-10. |
參考文獻: |
1. Ihara M, et al. J Cardiovasc Pharmacol. 1992, 12, S11-14. 2. Goyal SN, et al. Biomed Pharmacother. 2010, 64(9), 639-646. 3. Olgun NS, et al. Toxicol Appl Pharmacol. 2015, 282(3), 275-284. 4. Eguchi S, et al. FEBS Lett. 1992, 302(3), 243-246. 5. Erdogan H, et al. Hum Exp Toxicol. 2014, 33(10), 12008-12016. |
溶解性: |
Soluble in DMSO、Ethanol |
保存條件: |
-20℃ |
配置溶液濃度參考: |
|
1mg |
5mg |
10mg |
1 mM |
1.637 ml |
8.187 ml |
16.375 ml |
5 mM |
0.327 ml |
1.637 ml |
3.275 ml |
10 mM |
0.164 ml |
0.819 ml |
1.637 ml |
50 mM |
0.033 ml |
0.164 ml |
0.327 ml |
|
注意: |
部分產品我司僅能提供部分信息,我司不保證所提供信息的權威性,僅供客戶參考交流研究之用。 |